Absynth Biologics

Learn more about innovations in vaccine development



Absynth Biologics aims to discover and develop vaccines to prevent and treat common bacterial infections. With antibiotic resistance on the rise, the development of vaccines to prevent drug-resistant infections, such as staph, could have huge implications for hospital budgets and patients alike.

With five patent families already filed support the two initial vaccines under development, Absynth Biologics is looking to take the next step in its growth.

Clare Brown

If successful, Absynth’s programme will play an important part in combatting the problem of antibiotic resistance.

Claire Brown
Investment Manager with Alderley Park Ventures, Absynth lead investor


Register your interest below

Interested in finding out more about this unique investment opportunity? Let us know. 

Please note: as this is a private opportunity, you will need to self-certify as a high-net-worth individual or sophisticated investor to register your interest. You can do this by going to your profile. 

Already a SyndicateRoom member? Log in